Deal Listings

Cancer vaccine specialist in PLUS IPO

Oct 08 issue

A company developing a pipeline of cancer vaccines has raised £1.55 million in an initial public offering (IPO) on PLUS. Scancell raised the money through AIM-listed broker St Helen’s Capital.

The proceeds of the 60p placing will enable Scancell to start generating revenues from licensing its technology to other companies involved in the discovery and development of therapeutic vaccines.

The company also intends to secure regulatory approval to initiate clinical trials
of its own vaccine for the treatment of melanoma, which it hopes to begin next year.

Scancell, a spin-out from Nottingham University, has secured more than £6 million in private equity and other funding to date. The company is led by CEO Lindy Durrant, and commercial director Richard Goodfellow, a former director of licensing
at Scotia Pharmaceuticals.


Editor's View Business Bulletin Trailblazers Business Tools Finance Expansion Strategy Leadership Flotation Exits Columns Enterprise News Deal Listings Backchat	Deal Listings Cancer vaccine specialist in PLUS IPO Oct 08 issue A company developing a pipeline of cancer vaccines has raised £1.55 million in an initial public offering (IPO) on PLUS. Scancell raised the money through AIM-listed broker St Helen’s Capital. The proceeds of the 60p placing will enable Scancell to start generating revenues from licensing its technology to other companies involved in the discovery and development of therapeutic vaccines. The company also intends to secure regulatory approval to initiate clinical trials of its own vaccine for the treatment of melanoma, which it hopes to begin next year. Scancell, a spin-out from Nottingham University, has secured more than £6 million in private equity and other funding to date. The company is led by CEO Lindy Durrant, and commercial director Richard Goodfellow, a former director of licensing at Scotia Pharmaceuticals.